The Epigenetics Market to be Worth $5.47 Billion by 2030—Exclusive Report by Meticulous Research®”

  

“The Epigenetics Market to be Worth $5.47 Billion by 2030—Exclusive Report by Meticulous Research®”

According to a new market research report titled, ‘Epigenetics Market By Solution Type (Deviation, CAPA, Audit, Risk & Compliance, Inspection, Document, Change, Training Management) Deployment Mode (Cloud, On-premise) End User (Pharmaceutical, CDMO/CRO)—Global Forecast to 2030,’ published by Meticulous Research^®, the epigenetics market is projected to reach $5.47 billion by 2030 at a CAGR of 15.7% from 2023 to 2030.

Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5628

Epigenetics is phenotypic alteration without permanent genotypic change using several methods, including DNA methylation, histone modification, RNA modification, etc. These modifications play a crucial role in diagnosing and prognosis diseases and disorders. Epigenetics finds its major application in oncology due to the global cancer burden and the growing adoption of precision cancer therapies.

The growth of the epigenetics market is driven by the rising incidence of chronic diseases due to growth in the aging population, the increasing prevalence of cancer, rising pharmaceutical R&D expenditures, the increasing focus on epigenetics in drug discovery & development, and the declining costs of genome sequencing. However, the lack of skilled professionals restrains the growth of this market.

The growing applications of epigenetics in non-oncology diseases and government initiatives supporting large-scale genomic sequencing projects are expected to generate growth opportunities for the stakeholders in this market. However, standardization concerns associated with epigenetics procedures and the limited applications of epigenetics in toxicology are major challenges to market growth.

Growing Prevalence of Cancer is Driving the Demand for Epigenetics Offerings

Epigenetics enables pharmaceutical & biotechnology companies to identify and validate disease interactions and mechanisms that can be used in developing new diagnostic tests and therapies. Epigenetic markers are measurable indicators of a biological state or process that can be used to diagnose, monitor, or predict the progression of a disease and identify changes in gene expression, genetic variations, or epigenetic modifications associated with a particular disease or condition.

Biotechnology companies utilize epigenetic methods to identify factors influencing cell or gene interactions, reduce the time required to understand factors causing diseases and enable early diagnosis and treatment.

Request Sample Report Here @ https://www.meticulousresearch.com/request-sample-report/cp_id=5628

The report also includes an extensive assessment of the key strategic developments of leading market participants in the industry over the past years (2020–2022). In the last couple of years, the global Epigenetics Market witnessed several strategic developments.

The key players operating in the global Epigenetics Market are Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), New England Biolabs (U.S.), Epigentek Group Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), PerkinElmer, Inc. (U.S.), 10X Genomics, Inc. (U.S.), Active Motif (U.S.), and Zymo Research Corporation (U.S.).

The global epigenetics market study presents historical market data in terms of values (2021 and 2022), estimated current data (2023), and forecasts for 2030. The global epigenetics market is segmented by offering, method, application, and end user. The study also evaluates industry competitors and analyzes their market share at global and regional levels.

Based on offering, the epigenetics market is segmented into kits & reagents, software, and services. The kits & reagents segment is expected to grow at the highest CAGR during the forecast period. Kits & reagents are used to study epigenetics through chromatin analysis, histone analysis, DNA methylation, and sequencing, among other methods. Kits are ready-to-use assays that include components such as primers, controls, columns, buffers, beads, inhibitors, and antibodies, depending on the method used for analysis. Reagents are sold separately and can be used in different concentrations depending on the requirements of the procedure/analysis. The recurrent use of kits and reagents and the growing cancer prevalence are the major factors attributed to the segment's fast growth.

Based on method, the global epigenetics market is segmented into DNA methylation, histone modification, RNA modification, polymerase chain reaction (PCR), chromatin analysis, sonication, and other methods. In 2023, the DNA methylation segment is expected to account for the largest share of the epigenetics market. DNA methylation is an epigenetic mechanism that involves transferring a methyl group onto the C5 position of cytosine to form 5-methylcytosine. This process regulates gene expression by promoting or inhibiting the binding of transcription factors to DNA. Thus, it is useful in studying epigenetic changes in an organism. The increasing prevalence of cancer, technological advancements in PCR and sequencing, and the high focus on reducing costs associated with lengthy research and product approval processes support the segment’s large share.

Quick Buy @ https://www.meticulousresearch.com/Checkout/10022421

Based on application, the global epigenetics market is segmented into oncology and non-oncology. In 2023, the oncology segment is expected to account for the largest share of the market. Epigenetics helps differentiate the nuclear organization, DNA methylation, and histone modification patterns between cancer and normal cells. Several changes in cancer cells, such as lower histone post-translational modifications (methylation or acetylation), are associated with poor outcomes in prostate, lung, and kidney cancers. In contrast, higher levels of a specific histone modification (H3K9ac) are associated with lower survival in lung cancer. Also, a reduction in miR-101 expression has been observed in many cancer types, which leads to increased expression of an enzyme responsible for histone methylation. Such methylation induction in tumor suppressor genes can increase the risk of cancer development. Thus, epigenetic analyses help in the study, early diagnosis, and treatment of cancer, leading to a large segment share.

Based on end user, the global epigenetics market is segmented into pharmaceutical and biotechnology companies, academic & research institutes, and hospitals & diagnostic laboratories. The pharmaceutical and biotechnology companies segment is expected to grow at the highest CAGR during the forecast period. The highest CAGR of the segment is attributed to increasing R&D investments by pharmaceutical & biotechnology companies, the growing prevalence of chronic diseases, and a growing emphasis on personalized medicine.

The utilization of epigenetic analysis is growing in precision medicine. Advancements in epigenetic analysis are changing how doctors diagnose and treat cancer. New targeted cancer treatments that use genomic data to provide patient-specific treatments are known as precision oncology. This rapidly developing field has already become a part of mainstream clinical practices. It involves the molecular profiling of cancer cells to identify targetable alterations, also known as biomarkers. Quick and reliable sequencing of multiple genes at once is possible with epigenetic analysis. Epigenetic analysis has helped develop precision medicine, which involves tailoring treatments based on disease-causing molecular/epigenetic changes in a person’s body.

In 2023, North America is expected to account for the largest share of the Epigenetics Market. North America’s large market share is primarily attributed to the strong focus of local companies on product launches and enhancements, the presence of key players, the established healthcare system, the growing number of chronic diseases, and the rising geriatric population.

Top 10 Companies in Epigenetics Market @ https://meticulousblog.org/top-10-companies-in-epigenetics-market/

 

About Meticulous Research®

Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. With the meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.

Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research